What is the appropriate aztreonam dosing for an adult with an Escherichia coli urinary tract infection?

Aztreonam Dosing for E. coli UTI

For an adult with an E. coli urinary tract infection, aztreonam should be dosed at 500 mg to 1 g every 8-12 hours intravenously or intramuscularly, with the specific dose and interval determined by infection severity and renal function.

Dosing by UTI Type

Uncomplicated UTI

• 500 mg every 8-12 hours is appropriate for simple urinary tract infections 1
• This lower dose achieves urinary concentrations that exceed the MIC90 for E. coli for up to 12 hours 1
• Clinical studies demonstrate 84-89% microbiological cure rates with 1 g doses given 2-3 times daily for 5 days 2

Complicated or Severe UTI

• 1 g every 8-12 hours for moderately severe infections 1
• Consider the higher end of dosing (1 g every 8 hours) if the patient has:
  • Pyelonephritis
  • Systemic symptoms
  • Known or suspected resistant organisms
  • Comorbidities affecting immune response

Route of Administration

Use intravenous route for:

• Doses greater than 1 g
• Severe systemic infections
• Pyelonephritis with systemic involvement
• Patients unable to tolerate intramuscular injections 1

Intramuscular administration is acceptable for:

• Doses of 500 mg or 1 g
• Less severe UTIs
• Outpatient management when appropriate

Renal Dose Adjustments

This is critical as aztreonam is renally cleared:

CrCl 10-30 mL/min:

• Give normal loading dose (1-2 g)
• Then reduce maintenance dose by 50% at usual intervals 1

CrCl <10 mL/min (including hemodialysis):

• Give normal loading dose
• Maintenance: one-fourth of usual dose at standard intervals
• For hemodialysis: give one-eighth of initial dose after each dialysis session 1

Elderly patients:

• Estimate creatinine clearance (serum creatinine alone is unreliable)
• Adjust doses based on calculated CrCl 1

Duration of Therapy

• Continue for at least 48 hours after symptom resolution or evidence of bacterial eradication 1
• Typical duration: 5-10 days for most UTIs 2, 3
• Persistent infections may require several weeks 1

Important Clinical Considerations

Pharmacokinetic Advantages

Aztreonam achieves excellent urinary concentrations:

• 1100 mcg/mL within 2 hours after 500 mg IV dose
• 3500 mcg/mL after 1 g IV dose
• 6600 mcg/mL after 2 g IV dose 1
• These levels far exceed MIC90 for E. coli

When to Consider Aztreonam for E. coli UTI

Appropriate scenarios:

• Multidrug-resistant E. coli with documented aztreonam susceptibility 3, 4
• ESBL-producing E. coli (though newer agents like ceftazidime-avibactam are preferred) 5
• Penicillin/cephalosporin allergy in patients requiring parenteral therapy 3
• Aminoglycoside-sparing regimen when nephrotoxicity is a concern 4

Critical caveat: Aztreonam has NO activity against gram-positive organisms or anaerobes 3, 4. If mixed infection is suspected (e.g., complicated UTI with possible enterococcal involvement), combination therapy is mandatory.

Resistance Considerations

For NDM-producing E. coli (metallo-β-lactamase):

• Some isolates remain aztreonam-susceptible 6
• Combination therapy strongly recommended: aztreonam + ceftazidime-avibactam or aztreonam + amoxicillin-clavulanate 7
• Monotherapy risks treatment failure due to co-production of other β-lactamases 6

Monitoring

• Renal function: Monitor creatinine clearance, especially in elderly patients 1
• Clinical response: Expect improvement within 48-72 hours
• Adverse effects: Generally well-tolerated; transient LFT elevations possible 8

Common Pitfalls to Avoid

1. Don't use aztreonam empirically for UTI without considering local resistance patterns—it's not a first-line agent
2. Don't forget renal dose adjustment—failure to reduce dose in renal impairment risks toxicity
3. Don't use as monotherapy if gram-positive or anaerobic co-infection is possible
4. Don't underdose—while 2 g daily total has shown efficacy 9, standard dosing (3-4 g daily) is preferred for reliability